Immutep Ltd has released a press release.
Efti with Keytruda shows encouraging activity in lung cancer
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Immutep announces publication of ELCC 2022 abstract
- Japanese patent granted for LAG-3 antibody LAG525
- Immutep receives FDA feedback for Efti development in MBC
- Australian Patent Granted for Efti with PD-1 Inhibitors
- Immutep Advances IMP761 Manufacturing
Later from Immutep
- Immutep to announce new TACTI-002 data at ASCO 2022
- New & significant data from AIPAC phase 2b trial in MBC
- Immutep announces publication of ASCO 2022 abstracts
- Webcast slides for 1st line NSCLC data from TACTI-002 trial
- Immutep granted Japanese Patent for IMP761
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep